A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Trial Profile

A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs JCAR 015 (Primary)
  • Indications B-cell leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 22 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 01 Feb 2018 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top